In an interview last week, Larry Cohen — CEO of Health 2047, the American Medical Association’s venture studio — noted that digital health programs have proven to do a good job of improving patient outcomes — but only for certain groups. As technology continues to advance, he urged healthcare leaders not to underestimate the effectiveness of engaging patients by having boots on the ground.
Read news from PromptHealth, HealthMine, Health2047, Sound Life Sciences, and more.
Called RecoverX, the company will leverage AI to mine evidence-based research, medical charts, patient conversations and test results and provide clinical insights for clinicians in real time.
The health plan hopes to better address the needs of underserved populations through community-based teams that can understand and overcome social barriers to care.
A panel discussion at the upcoming MedCity INVEST meeting in Chicago will look at real-world applications of blockchain technology in healthcare and biopharma.
With $2 million in seed funding, the company, First Mile Care, is utilizing a coaching and support model in an effort to reverse prediabetes.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
"If you just introduce technologies but don't embed them in a practical user experience, they're not going to be helpful," Lúcia Soares, managing director at Health2047, said in a phone interview.
Health2047 CEO Lawrence Cohen outlined the company's strategy following the group's first spinoff last year of health data network business Akiri, previously known as Switch.
The launch of the business is intended to make it easier to transmit data between pharmacies, patients and physicians. It's also part of a wider effort by Health2047, affiliated with the American Medical Association, to make clinicians a driving force in health IT innovation.
Health2047 Switch is one of several new businesses the group plans to launch.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Dr. Doug Given, Health2047 CEO, said In a phone interview that Celgene is the first of many collaboration partners that will be announced this year.
A look at some of the hidden challenges of diabetes management and how the patient experience can be improved.
In emailed responses to questions, Given said it wanted to use its lab to create more effective product strategies by getting more input from physicians.
